ES2561674T3 - Antagonistas de TRPV4 - Google Patents

Antagonistas de TRPV4 Download PDF

Info

Publication number
ES2561674T3
ES2561674T3 ES11760129.4T ES11760129T ES2561674T3 ES 2561674 T3 ES2561674 T3 ES 2561674T3 ES 11760129 T ES11760129 T ES 11760129T ES 2561674 T3 ES2561674 T3 ES 2561674T3
Authority
ES
Spain
Prior art keywords
4alkyl
independently
morpholinyl
piperidinyl
pyrrolidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11760129.4T
Other languages
English (en)
Inventor
Carl A. Brooks
Mui Cheung
Hilary S. Eidam
Ryan M. Fox
Mark A. Hilfiker
Eric S. Manas
Guosen Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Application granted granted Critical
Publication of ES2561674T3 publication Critical patent/ES2561674T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de Fórmula I:**Fórmula** en donde: R1 es independientemente H, CF3 o Me; R2 es independientemente OH, Oalquilo C1-4, alquilo C1-4, CH2OH, F, CH2Oalquilo C1-4, CF3 o CF2H; R3 es morfolinilo, piperidinilo, pirrolidinilo o hexahidroazepinilo; todos los cuales pueden estar sin sustituir o sustituidos con uno o dos R8; o R3 es N(alquilo C1-6 )2, en donde alquilo C1-6 puede estar sin sustituir o sustituido con OH o -OCH3; R4 es CF3, halo, OMe o alquilo; R5 es halo, ciano, CF3, alquilo C1-5, alquenilo C2-4, pirrolidinilo, morfolinilo, piperidinilo, fenilo, piridilo, pirazolilo, pirrolilo, piperazinilo, pirimidinilo, OH, O-alquil C1-4-OR6, OCF3, OCH2CF3, OCH2CN, OR6 o CH2R9; en donde el pirrolidinilo, morfolinilo, piperidinilo, fenilo, piridilo, pirazolilo, pirrolilo, piperazinilo o pirimidinilo puede estar sin sustituir o sustituido con uno o dos halo, OH, OR6 o R6; R6 es independientemente alquilo C1-4, cicloalquilo C3-6; R7 es independientemente halo, metilo o OMe; R8 es independientemente OH, Oalquilo C1-4, alquilo C1-4, CH2OH, F, CH2Oalquilo C1-4, CF3 o CF2H; R9 es independientemente pirrolidinilo, morfolinilo o piperidinilo; R10 es independientemente H, CF3 o Me; n es independientemente 0, 1 o 2; X es N o C; y es 1 o 2; o una de sus sales farmacéuticamente aceptables.
ES11760129.4T 2010-03-23 2011-03-23 Antagonistas de TRPV4 Active ES2561674T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31643210P 2010-03-23 2010-03-23
US316432P 2010-03-23
PCT/US2011/029579 WO2011119701A1 (en) 2010-03-23 2011-03-23 Trpv4 antagonists

Publications (1)

Publication Number Publication Date
ES2561674T3 true ES2561674T3 (es) 2016-02-29

Family

ID=44673594

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11760129.4T Active ES2561674T3 (es) 2010-03-23 2011-03-23 Antagonistas de TRPV4

Country Status (5)

Country Link
US (1) US8658636B2 (es)
EP (1) EP2549872B1 (es)
JP (1) JP5819397B2 (es)
ES (1) ES2561674T3 (es)
WO (1) WO2011119701A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013146754A1 (ja) 2012-03-27 2013-10-03 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
WO2014089013A1 (en) 2012-12-03 2014-06-12 Indiana University Research And Technology Corporation Use of trpv4 antagonists to ameliorate hydrocephalus and related materials and methods
WO2015046193A1 (ja) 2013-09-25 2015-04-02 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
EP3585371B1 (en) 2017-02-24 2024-07-10 Indiana University Research and Technology Corporation Methods of inhibiting serum glucocorticoid induced kinase 1 (sgk1) as a treatment for salt and water balance diseases
US20230339934A1 (en) 2020-04-30 2023-10-26 Raqualia Pharma Inc. Pyrimidin-4(3h)-one derivatives as trpv4 antagonists
JPWO2022014707A1 (es) 2020-07-16 2022-01-20

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
MXPA01005095A (es) * 1998-11-20 2002-04-24 Smithkline Beecham Spa Derivados de quinolin-4-carboxamida como antagonistas de receptor de neurocinina-3 y neurocinina-2.
US6511649B1 (en) * 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
SE0004054D0 (sv) * 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
US20070197509A1 (en) 2005-12-21 2007-08-23 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
WO2010011914A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Trpv4 antagonists
WO2011119693A1 (en) * 2010-03-23 2011-09-29 Glaxosmithkline Llc Trpv4 antagonists

Also Published As

Publication number Publication date
EP2549872A4 (en) 2014-08-06
EP2549872A1 (en) 2013-01-30
US20130012499A1 (en) 2013-01-10
WO2011119701A1 (en) 2011-09-29
JP5819397B2 (ja) 2015-11-24
US8658636B2 (en) 2014-02-25
EP2549872B1 (en) 2015-11-25
JP2013522372A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
ES2561674T3 (es) Antagonistas de TRPV4
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
EA201591429A1 (ru) 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена
ECSP14020586A (es) Composición para el control de plagas que incluye un derivado de iminopiridina novedoso
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AR090539A1 (es) COMPUESTOS INHIBIDORES DE b LACTAMASA
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR085150A1 (es) Agentes moduladores de s1p
AR073136A1 (es) Compuestos de pirrol
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR059925A1 (es) Formulaciones
AR078641A1 (es) Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
AR086958A1 (es) Antagonistas de trpv4
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR083903A1 (es) Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos
AR085920A1 (es) Derivados benzimidazolicos utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR066154A1 (es) Derivados de piperidina / piperazina
AR086934A1 (es) Inhibidores del virus de la hepatitis c